News & Updates

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

Among fixed-dose combinations of inhaled corticosteroids/long-acting beta-2-adrenergic agonists (ICS/LABA), the newer combinations of fluticasone furoate/vilanterol (FF/VI) and fluticasone propionate/formoterol (FP/FORM) are associated with increased treatment persistence and lead to fewer exacerbations among patients with asthma, as shown in a study.

In the phase II/III EPIC-HR* trial, the novel oral antiviral nirmatrelvir-ritonavir reduced the risk of progression of COVID-19 to severe disease, as well as viral load, in symptomatic, high-risk, unvaccinated nonhospitalized adults confirmed to have SARS-CoV-2 infection.

Use of either empiric broad- or narrow-spectrum antibiotics in older patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) shows no remarkable difference in the primary outcome, reports a recent study.

Nearly one in four nonidiopathic pulmonary fibrosis (non-IPF) patients with a fibrosing form of interstitial lung disease (FILD) develop a progressive phenotype relative to almost 60 percent of IPF patients, reveals a study. Survival of non-IPF FILD patients with such phenotype is similar to IPF.